These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 12877583)
1. Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model. Graffner-Nordberg M; Fyfe M; Brattsand R; Mellgård B; Hallberg A J Med Chem; 2003 Jul; 46(16):3455-62. PubMed ID: 12877583 [TBL] [Abstract][Full Text] [Related]
2. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases. Gangjee A; Vasudevan A; Queener SF; Kisliuk RL J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases. Gangjee A; Elzein E; Queener SF; McGuire JJ J Med Chem; 1998 Apr; 41(9):1409-16. PubMed ID: 9554874 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. Gangjee A; Adair OO; Queener SF J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957 [TBL] [Abstract][Full Text] [Related]
5. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents. Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases. Gangjee A; Shi J; Queener SF J Med Chem; 1997 Jun; 40(12):1930-6. PubMed ID: 9191971 [TBL] [Abstract][Full Text] [Related]
7. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Al-Rashood ST; Aboldahab IA; Nagi MN; Abouzeid LA; Abdel-Aziz AA; Abdel-Hamide SG; Youssef KM; Al-Obaid AM; El-Subbagh HI Bioorg Med Chem; 2006 Dec; 14(24):8608-21. PubMed ID: 16971132 [TBL] [Abstract][Full Text] [Related]
9. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity. Rosowsky A; Forsch RA; Sibley CH; Inderlied CB; Queener SF J Med Chem; 2004 Mar; 47(6):1475-86. PubMed ID: 14998335 [TBL] [Abstract][Full Text] [Related]
10. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim. Rosowsky A; Papoulis AT; Forsch RA; Queener SF J Med Chem; 1999 Mar; 42(6):1007-17. PubMed ID: 10090784 [TBL] [Abstract][Full Text] [Related]
12. Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. Rosowsky A; Forsch RA; Queener SF J Med Chem; 2003 Apr; 46(9):1726-36. PubMed ID: 12699390 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents. Gangjee A; Lin X; Kisliuk RL; McGuire JJ J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. Gangjee A; Yu J; McGuire JJ; Cody V; Galitsky N; Kisliuk RL; Queener SF J Med Chem; 2000 Oct; 43(21):3837-51. PubMed ID: 11052789 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523). Rosowsky A; Wright JE; Vaidya CM; Bader H; Forsch RA; Mota CE; Pardo J; Chen CS; Chen YN J Med Chem; 1998 Dec; 41(26):5310-9. PubMed ID: 9857098 [TBL] [Abstract][Full Text] [Related]